INCIDENCE AND RISK FACTORS FOR FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA
Main Article Content
Abstract
Objectives: To determine the incidence of febrile neutropenia (FN) and identify related risk factors in patients with non-Hodgkin’s lymphoma (NHL). Methods: A retrospective, cross-sectional descriptive study was conducted on 100 newly diagnosed NHL patients treated at Military Hospital 103 from May 2021 to May 2025, with research parameters including clinical characteristics, paraclinical findings before and after each treatment cycle, and treatment methods. Results: The incidence of FN was 32%, with 25% occurring after the first chemotherapy cycle. The study identified several statistically significant risk factors for FN, including rapid weight loss prior to treatment (OR = 3.25; p = 0.008), ECOG score ≥ 2 (OR = 3.96; p = 0.009), IPI score of 3 - 4 (OR = 3.53; p = 0.005), anemia (OR = 2.72; p = 0.022), elevated LDH levels (OR = 2.45; p = 0.043), and hypoalbuminemia (OR = 2.90; p = 0.022). Hematological indices, including the NLR and NMLR, were significantly elevated in the FN group compared to the non-FN group. Conclusion: FN is a common and significant complication in NHL patients undergoing chemotherapy. Identifying key risk factors such as poor physical status, malnutrition, high tumor burden, and hematological changes can support early risk stratification and guide individualized prophylactic strategies.
Keywords
Non-Hodgkin’s lymphoma, Febrile neutropenia, Risk factor
Article Details
References
2. Morimoto M. Development of a predictive model for febrile neutropenia after chemotherapy in patients with non-Hodgkin’s lymphoma and diffuse large B cell lymphoma. St. Luke’s International University. 2022.
3. Yokoyama M, et al. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). 2020; 28(2):571-579.
4. Go S-I, et al. Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia. 2025; 33(7):533.
5. Choi YW, et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-Cell lymphoma patients treated with Rituximab-CHOP. J Korean Med Sci. 2014; 29(11):1493-1500.
6. Morimoto M, et al. Predictive model for occurrence of febrile neutropenia after chemotherapy in patients with diffuse large B-cell lymphoma: A multicenter, retrospective, observational study. Hematol dep. 2024; 16(1):76-88.
7. Hardianti M, et al. Risk factors for neutropenia after the first cycle of chemotherapy for non-Hodgkin lymphoma. Eur J Med Health Sci. 2021; 3(6):73-77.
8. Bakirtas M, et al. Febrile neutropenia risk factors in actively treated diffuse large B-cell lymphoma patients. 2022; 11(1):7-12.
9. Kim YR, KS, Kim SH, et al. Risk factors of febrile neutropenia in non-Hodgkin’s lymphoma patients receiving chemotherapy with prophylactic pegylated G-CSF. Ann Hematol. 2021;100(6): 1429-1438.
10. Shih M-f, et al. Association between the neutrophil-to-lymphocyte ratio and infection and survival in diffuse large B cell lymphoma. 2023; 37(2):948-954.